Purpose: Contrast-induced acute kidney injury or contrast-induced nephropathy (CIN) is a significant complication of intravascular contrast medium (CM). These guidelines are intended as a practical approach to risk stratification and prevention. The major risk factor that predicts CIN is pre-existing chronic kidney disease. Methods: Members of the committee represent radiologists and nephrologists across Canada. The previous guidelines were reviewed, and an in-depth up-to-date literature review was carried out. Results: A serum creatinine level (SCr) should be obtained, and an estimated glomerular filtration rate (eGFR) should be calculated within 6 months in the outpatient who is stable and within 1 week for inpatients and patients who are not stable. Patients with an eGFR of 60 mL/min have an extremely low risk of CIN. The risk of CIN after intra-arterial CM administration appears be at least twice that after intravenous administration. Fluid volume loading remains the single most important measure, and hydration regimens that use sodium bicarbonate or normal saline solution should be considered for all patients with GFR < 60 mL/min who receive intra-arterial contrast and when GFR < 45 mL/min in patients who receive intravenous contrast. Patients are most at risk for CIN when eGFR < 30 mL/min. Additional preventative measures include the following: avoid dehydration, avoid CM when appropriate, minimize CM volume and frequency, avoid high osmolar CM, and discontinue nephrotoxic medications 48 hours before administration of CM.
Contrast-induced nephropathy (CIN) is the development of acute kidney injury (AKI) after the administration of radiographic contrast media (CM) in the absence of other identifiable causes and is widely accepted as a leading cause of hospital-acquired AKI. Radiologists play a pivotal role in the responsible use of CM and in the implementation of preventative measures to reduce the risk of CIN. These guidelines are meant to represent a practical and implementable approach to the identification and management of patients at risk of CIN.
Prospective studies of patients admitted with AKI demonstrate that intravascular CM was responsible or contributory in 11%-14.5% of cases [1e3] , which supports the widespread view that CIN is one of the leading causes of AKI. The development of AKI is thus considered a significant complication of radiographic CM use and has been linked with both excess morbidity and mortality [4, 5] . The most common procedures associated with CIN in those studies are coronary angiography and contrast-enhanced computed tomography (CT). The use of contrast-enhanced CT is increasing rapidly, and the total amount of CM used in radiology departments is also increasing [5] . These factors, coupled with an increased incidence of chronic kidney disease and an aging population, will result in an increased incidence of CIN unless effective preventative measures are taken. Before contrast is administered, patients should be fully assessed, and precautions must be taken with patients with renal impairment. Implementation of prevention strategies is considered to be the best approach to reducing the development of CIN [6] .
Methodology
Members of the committee represent interventional and diagnostic radiologists and nephrologists across Canada. The previous guidelines [7] were reviewed, changes in guidelines from individual radiology departments in Edmonton, Ottawa, and Oshawa were also reviewed. An in-depth up-to-date literature review was carried out to encompass new publications. A consensus document was drawn up by the lead author and reviewed by all members of the committee before release of the final document. The document was then made available to stakeholders and Canadian Association of Radiologist (CAR) members for review before CAR board review and availability on the CAR Web site.
Definition of CIN
CIN is an acute decline in renal function that occurs 48-72 hours after intravascular injection of CM [7] . The most common definitions in use are an increase in serum creatinine (SCr) level of >25% of the baseline value or an absolute increase in the SCr level by at least 44 mmol/L that occurs after the intravascular administration of CM without an alternative explanation [8] . SCr usually peaks 48-72 hours after CM use and returns to the baseline within 14 days; however, some patients may progress to acute kidney injury that requires dialysis [9] .
Renal Function Estimates
Renal impairment can be expressed by using a variety of indices of renal function, including the SCr level, glomerular filtration rate (GFR), and creatinine clearance (CrCl) [10] . GFR and CrCl are to all intents and purposes similar, and although there is variance, particularly when there is a profound reduction in renal function (due to a compensatory increase in tubular secretion), for the purposes of this document, they are considered interchangeable. Despite widespread use in clinical practice, the SCr level, as an absolute measure, is an unreliable indicator of kidney function. GFR is considered to be a more appropriate index of kidney function and can be estimated from the SCr level (see below) [11] .
Clinical Outcomes
CIN remains one of the most serious adverse effects associated with the use of CM [12] . Patients with CIN experience more systemic and cardiac in-hospital complications than patients without CIN [4] . In-hospital death rates increase significantly among patients with CIN, as do the number of days in the intensive care unit, number of days in the hospital, and the need for dialysis [1, 11] . Among patients who require dialysis, the median 2-year survival rate is 19% [1] . Even patients who do not require dialysis have dramatically increased mortality rates at 1 year [13] .
At-Risk Patients
The single most important predictor of CIN risk is chronic kidney disease (CKD), which increases the risk by more that 20 times [12] . Risk can be further stratified according to the National Kidney Foundation Kidney Diseaase Quality Initiative (KDOQI) classification based on estimated glomerular filtration rate (eGFR) [10] . It is widely accepted that the risk of developing CIN in patients with eGFR 60 mL/min is extremely low. Results of several studies have also indicated that a threshold for CIN exists when the eGFR is 40-45 mL/min and that efforts to reduce the risk of CIN should be concentrated in patients with eGFR < 45 mL/min with special emphasis of those patients with severe CKD (eGFR < 30 mL/min) [14] . Comorbidities are also important, and patients with both renal impairment and diabetes are at highest risk, with up to 50% developing CIN [15] . Patients should be assessed for the presence of factors predictive of possible pre-existing chronic renal failure or risk of acute renal failure, particularly sepsis and hypotension (Table 1) .
Identifying Patients at Risk
Routine measurement of SCr in all patients undergoing injection of intravascular CM is logistically impractical, may delay investigation, may disrupt bookings, and has an associated cost [16, 17] . Fortunately, the majority of patients who develop CIN have identifiable risk factors, and results from numerous studies suggest that the occurrence of CIN is directly related to the number of pre-existing risk factors [18e20]. In a study of CIN, 32% of patients were diabetic, 40% had pre-existing renal disease, and 16% had both diabetes and renal disease [12] . Therefore, it is important to identify patients who may be most vulnerable [5, 21] . Methods to identify patients at risk include use of patient questionnaires, a review of the patient's complete medical history, and measurement of SCr before CM administration.
The absence of risk factors for renal disease effectively eliminates the likelihood of a patient having renal impairment.
In a study of 2034 consecutive outpatients referred for CT, only 2 patients (0.1%) had an elevation in SCr value in the absence of risk factors. The conclusion from this study was that, by identifying risk factors, the majority of patients with CKD would be identified [16] . This view is supported by other studies [20, 22, 23] . As a minimum requirement, it, therefore, is recommended that the SCr value (and eGFR) be obtained up to 6 months before the contrast procedure in the stable outpatient with one or more of the listed risk factors but without significant renal impairment and up to 1 week for inpatients and patients with unstable or acute renal disease. In some institutions, it may be considered safer and more practical to obtain an SCr level systematically in all patients referred for iodinated CM injection.
Patients in the Emergency Department
In patients who are acutely ill, delays in imaging while awaiting SCr level results may adversely affect patient care. Fortunately, evaluation of patients' known risk factors will identify almost all patients with renal impairment [24] . In situations in which the contrast procedure cannot be delayed, if the patient's medical history reveals one or more risk factors for renal impairment, then preventive measures (particularly preprocedural fluid administration) should be implemented empirically rather than risk deterioration of the patient's clinical status. It is often possible to administer a bolus of 300-500 mL of intravenous (IV) fluid during the time required to transfer the patient to the imaging department.
Risk Stratification Based on eGFR
Radionuclide techniques give the most accurate measurement of GFR but are labor intensive and expensive [25] . Clinical assessment of GFR is usually based on plasma or SCr level results. The SCr level reflects both muscle production of creatinine and renal excretion. It, therefore, is not reasonable to classify risk or base therapeutic decisions on the absolute value of SCr as a measure of renal function, without factoring for muscle mass. GFR can be accurately estimated from predictive equations that take into account SCr levels and factors predictive of muscle mass; any such calculation, however, will be subject to issues that affect the creatinine measurement, including age; female sex; African, Asian, or Hispanic ethnicity; extremes of muscle mass; and nutritional status. The modification of diet in renal disease and Cockcroft-Gault equations are valid in adults; the Schwartz and Counahan-Barratt equations are valid in children [10] . The MDRD formula uses the SCr level, age, and sex to estimate GFR and is reported in mL/min per 1.73 m 2 . It can readily be calculated by clinical laboratories and is already reported routinely in many parts of Canada. The Cockcroft-Gault equation uses the SCr level, age, sex, and weight, and gives a result in mL/min. Both equations, in general, are more accurate estimates of GFR than 24-hour urine creatinine clearance values. Both equations assume [10] . As shown in Figure 1 , after intra-arterial (IA) contrast, a 65-year-old man who weighs 72 kg, with an eGFR of approximately 30 mL/min, has approximately a 30%-40% risk of developing CIN.
It is recommended that risk assessment and prophylactic strategies be based on eGFR rather than the absolute level of SCr:
A eGFR 60 mL/min: very low risk for CIN. These patients require no specific prophylaxis or follow up. 
Route of CM Administration
The majority of publications regarding CIN has been of patients undergoing IA contrast administration, in particular, in the cardiac setting. It has been widely assumed that the risks were similar after IV CM administration, particularly in the CT setting. Several recent publications question this assumption [13,27e29] . In 2 clinical trials of patients who received IV contrast, which involved 1075 patients, only 1 case of CIN was observed in patients with an eGFR > 40 mL/min, and in the 55 patients who did develop CIN, none progressed to dialysis or had a fatal outcome [30, 31] . It, therefore, appears that the risk of CIN and, in particular, the risk of a serious outcome after IV contrast use, is significantly lower than that after IA contrast administration. Hence, we recommend full preventative measures for all patients with eGFR < 60 mL/min who are receiving IA contrast. However, for patients who receive IV contrast, IV hydration regimens are recommended when the eGFR < 45 mL/min.
Risk Factor Reduction
As a general guideline for all patients with eGFR< 60 mL/min, it is recommended that alternative imaging studies not requiring iodinated contrast be considered first. In patients with an eGFR < 60 mL/min who are receiving IA CM, nonessential nephrotoxic medications, such as nonsteroidal anti-inflammatory drugs, should be discontinued at least 48 hours before the procedure. Diuretics, especially furosemide, should be withheld at least the day before and the day of the procedure. (Holding diuretics is a recommendation made to the referring physician who must assess if the patient can safely be taken off this medication to decrease the risk of contrast nephropathy).
Fluid Administration
There is universal acceptance that fluid-volume loading is the single most important measure that can be taken before intravascular CM administration, and this approach is advocated in all recently published studies. All patients considered at risk for CIN should be fluid loaded. Isotonic saline and bicarbonate solution (which contains 3 ampoules per 154 mmol of sodium bicarbonate in 0.85 L 5% dextrose) are the 2 most commonly used crystalloids. Although initial studies and meta-analyses supported the use of sodium bicarbonate [32] , this beneficial effect has not been sustained in a number of subsequent trials and meta-analyses [33, 34] . The conclusion from the most recent meta-analysis was that the potential benefit, if any, of the bicarbonate-based solution over normal saline solution was likely to be very small in clinical practice. It would appear that there is little advantage in clinical practice of bicarbonate over normal saline solution. However, when hydration regimes by using sodium bicarbonate have been set up, it would reasonable to continue using them. 
IV Fluid Administration
A For inpatients, the standard recommendation is the following: 0.9% saline solution at 1 mL/kg/hr for 12 hours before the procedure and 12 hours after the procedure [35] .
A When patients need to be fluid loaded for procedures scheduled the same day: Isotonic saline solution or sodium bicarbonate solution at 3 mL/kg/hr, a minimum of 1 hour before the procedure and 6 hours after the procedure is a reasonable abbreviated alternative [26, 34] .
A Depending on the patient's weight, at least 300-500 mL of IV hydration should be administered before contrast is given [31] .
Oral Hydration
There is no substantial evidence that oral hydration has any effect on the incidence of CIN. It, however, is important to avoid fluid restriction; all patients should be encouraged to drink fluids and salt (eg, salty soup) for volume expansion before the investigation when practical. For patients who require a period of fasting, this should be kept to a minimum, in most circumstances, nil by mouth for 4 hours is sufficient, for example, before a procedure that requires sedation.
Volume and Frequency of Administration of CM
The prevalence of CIN correlates with CM volume with the lowest rates of CIN that occur in patients who receive less than 100-140 mL. CM volumes in excess of 5 mL/kg strongly predict nephropathy that require dialysis [36] . A significantly increased risk of CIN has also been demonstrated among patients who received a second dose of CM within 48 hours [37e39]. If possible, reasonable attempts to minimize contrast volume and to avoid repeated injections within 72 hours should be made. Use of the lowest concentration of iodinated contrast, in mg/mL, required to achieve satisfactory image quality is encouraged. It is often possible to dilute iodinated contrast further with normal saline solution without affecting image quality.
Metformin
Metformin is not a risk factor for developing CIN, and the injection of CM is not contraindicated in patients receiving it. However, serious complications (lactic acidosis) may rarely occur in patients who take metformin who subsequently develop AKI. For this reason, metformin often needs to be discontinued in patients undergoing contrast studies. Whether this should be done at the time of or 48 hours before the contrast injection and whether metformin must be held in all patients or only those with underlying renal insufficiency remain somewhat controversial. The monogram for Glucophage (metformin) (Merck Sante Corporation, Lyon, France) in the Compendium of Pharmaceuticals and Specialities [40] simply recommends that, with patients for whom any contrast study is planned, metformin should be discontinued at the time of or before the procedure and be withheld for 48 hours subsequent to the procedure, and reinstituted only after renal function has been reevaluated and found to be normal. The European Society of Urogenital Radiology adopts a conservative approach and recommends holding metformin at the time of injection in patients with a normal SCr level and 48 hours before injection for elective studies with patients with abnormal renal function [41] . Other researchers believe that there is no longer any requirement to stop metformin for 48 hours before contrast injection. This view is supported by the American College of Radiology [42] . In our opinion, the only exception would be in a patient with marked renal impairment (eGFR 30 mL/min) or in acute renal failure, when, if a contrast study is deemed necessary, it would be appropriate to stop metformin 48 hours before a nonurgent contrast injection. Furthermore, for these patients, the indication of using metformin should be reassessed by the clinical team, because the risk of metformin-induced lactic acidosis is high in those with eGFR < 30 mL/min, irrespective of CM administration. Conversely, the risk to patients with normal renal function is extremely low [40, 43] , and based on available evidence, certain researchers consider it unnecessary to discontinue metformin or recheck renal function after the use of normal volumes (<100 mL) of CM in patients with normal baseline renal function. In summary, as a minimum requirement, we suggest that:
A In patients with eGFR < 45 mL/min, metformin should be stopped at the time of contrast injection and should not be restarted for at least 48 hours and only then if renal function remains stable (<25% increase compared with baseline creatinine).
A It generally is unnecessary to stop metformin 48 hours before contrast injection, but special care should be taken in patients with severe or acute renal dysfunction.
Prophylactic Dialysis or Hemofiltration
CM can be easily removed with hemodialysis; however, there is no evidence that this removal reduces the risk of CIN. Reduction of CIN with dialysis is also not biologically plausible because the CM would reach the kidneys within 1 or 2 cardiac cycles, and subsequent removal of CM is unlikely to stop the cascade of renal injury, which would have already begun. Although 1 study [44] did show a reduction in CIN with hemofiltration, this result has not been reproduced by other studies and a meta-analysis [45, 46] . In patients who are already receiving renal replacement therapy, dialysis after CM administration may be helpful in individual situations only if volume loading has occurred.
Patients on Dialysis
Patients undergoing hemodialysis need not be fluid loaded before contrast administration. Coordination of contrast administration with the timing of hemodialysis is unnecessary. Nephrotoxicity remains a concern in patients who retain residual function, and in these patients, renal protective measures may be considered.
Choice of CM
Ionic and high-osmolar CM are associated with more adverse events overall, (including CIN), compared with low-osmolar and iso-osmolar CM, and their use should be avoided in patients with CKD. The iso-osmolar CM iodixanol (Visipaque, GE Healthcare, Salt Lake City, UT) became more widely used in patients with CKD after a study that suggested its superiority compared with iohexol (Omnipaque, GE Healthcare) in reducing CIN [47] . Larger studies and meta-analyses have failed to show a significant difference between iodixanol and most other low-osmolar CM [48, 49] . A report of the American College of Cardiology Foundation and the American Heart Association found that, despite inferences of differences among different lowosmolar and iso-osmolar agents, the strength and consistency of the relationships among specific agents and CIN or renal failure are inadequate to provide a guideline statement on selection among commonly used low-osmolar or isoosmolar media [50] . The current CAR recommendation is to use an iso-osmolar or low-osmolar CM in patients with eGFR < 45 mL/min for IV CM use and GFR < 60 mL/min for IA CM studies. However, a higher risk of iohexol compared with iodixanol cannot be entirely ruled out [47] . When IA CM is to be used, other considerations, for example, viscosity, may also influence the choice of CM. Many radiology departments use iso-osmolar CM with highrisk patients, especially those with eGFR < 30 mL/min, and local practice could dictate the choice between low-osmolar and iso-osmolar CM use.
Gadolinium
In catheter-based angiography, iodinated contrast should not be replaced by IA or IV gadolinium in an attempt to prevent CIN. IA injection of gadolinium is associated with nephrotoxicity [51] , and its safety in high-risk patients is unproven. In patients with eGFR < 30 mL/min who are at high risk of CIN, gadolinium also carries a risk of a rare and potentially fatal disease, nephrogenic systemic fibrosis [52, 53] . Hence, replacement of iodinated CM with gadolinium to reduce CIN is not recommended.
Carbon Dioxide
Carbon dioxide can be substituted for iodinated contrast in certain angiographic procedures; however, the user must be familiar with the technical aspects, the risks, and the interpretation of carbon dioxide angiography before considering this alternative. When used properly, there appears to be no significant nephrotoxicity associated with carbon dioxide.
Pharmacologic Preventative Strategies
Acetylcysteine N-Acetylcysteine (NAC) (Mucomyst, Bristol-Myers Squibb Co, New York, NY) has been in widespread use for the prevention of CIN in at-risk populations after an initial publication by Tepel at al [54] , in which 600 mg of NAC was given orally for 2 days before the procedure. Subsequently, NAC has been studied at higher doses (1200 mg twice a day for 48 hours) and as an IV formulation (total dose ranging from 2400 mg to 150 mg/kg) [55e57]. There have been widely conflicting results with more than 40 clinical trials and 13 meta-analyses [58] . There have been doubts raised about the artifactual effect of NAC on creatinine levels, which may drive the positive results [59] . Indeed, the most meticulous meta-analysis does not support the use of NAC to reduce CIN risk [60] . However, NAC use is not associated with major adverse effects (except with high-dose IV use, which carries a risk of anaphylactoid reactions) [54] , and its use is not generally contraindicated. It, however, should not be considered as a substitute for hydration.
Follow-up
A follow-up SCr level measurement is recommended 48-72 hours after CM injection in patients who receive IA CM and should be considered in those who receive IV CM with eGFR <45 mL/min.
Children
This document is targeted for adult patients; however, general principles hold true in pediatric patients, and when drugs and doses are mentioned, these can be tailored for use in children provided the doses are adjusted appropriately, no contraindications exist, and the products are licensed for use in children. Iodixanol (Visipaque) is not currently licensed in Canada for use in children.
Conclusion
CIN remains one of the most serious complications arising from the use of iodinated CM. The CAR considers risk prediction and preventative measures to avoid CIN necessary for optimum radiologic practice (see Appendix 1) . The most important risk factor for CIN is pre-existing renal impairment. Radiologists and referring physicians should be familiar with the risk factors for renal disease and CIN. The baseline renal function of patients undergoing contrast studies is best assessed with eGFR by using the modification of diet in renal disease or Cockcroft-Gault formulas in adults.
The SCr level is not a reliable indicator of renal function. Using eGFR to assign risk levels and implement prevention strategies is considered to be the best approach to reducing the incidence of CIN.
